MDACC Study No:2012-0054 ( NCT No: NCT01565668)
Title:A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal Investigator:Jorge Cortes
Treatment Agent:AC220
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the safety and
effectiveness of 2 doses of quizartinib in people with relapsed or refractory

The study drug is designed to block the FLT3 receptor on leukemia cells to stop
the chemical reaction that happens when FLT3 is activated. This may slow or
stop cancer cell division, and may lead to cancer cell death. Quizartinib may
also work against other receptors that are involved in leukemia cell division
and growth.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:AC220
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Ambit Biosciences Corporation
Leukemia SPORE
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults